Antidepressant Efficacy of the Antipsychotic Quetiapine:Pharmacokinetics, Pharmacodynamics and Clinical Data

  title={Antidepressant Efficacy of the Antipsychotic Quetiapine:Pharmacokinetics, Pharmacodynamics and Clinical Data},
  author={Mauri Mc and Chiara Rovera and Ciappolino and Concetta Dipace and Silvia Paletta and Alessandra Reggiori and Alfredo Carlo Altamura},
Quetiapine (QTP) is an is an atypical antipsychotic, that was approved in 1997 by American Food and Drug Administration (FDA) for schizophrenia, both in adults and adolescents (13-17 years). Since 2003 this drug was approved also for the treatment of maniac episode in bipolar adults and adolescents (10-17 years) then in 2006 FDA extended the use of QTP to bipolar depression episodes and in 2008 to the maintenance treatment of bipolar disorder. In 2009 QTP starts to be used also as add on… Expand
Antipsychotic therapeutic drug monitoring : evaluation of the role of oral fluid, and plasma quetiapine metabolite assays
A glossary of words and phrases used in the study of fruit and vegetable processing and their applications in the context of food and drink are provided. Expand


Quetiapine: a pharmacoeconomic review of its use in bipolar disorder.
Results of available pharmacoeconomic analyses provide evidence of the cost effectiveness of quetiapine as an adjunct to mood stabilizers for maintenance therapy in (primarily type I) bipolar disorder from a healthcare payer perspective in the UK and the US. Expand
[Quetiapin in bipolar disorders].
  • András Sümegi
  • Medicine
  • Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology
  • 2008
Clinical data and actual research results suggest that comparing to other atypical antipsychotics, norquetiapine may have a relatively strong antidepressant potential, which may explain its long-term antimanic and mood stabilizing capability. Expand
Clinical highlights in bipolar depression: focus on atypical antipsychotics.
Subpopulation analyses suggest that quetiapine monotherapy and the olanzapine plus fluoxetine combination appear to be effective in treating depression in patients with a rapid-cycling course, and the magnitude of improvement in depressive symptoms in the bipolar I population appears to be larger for queto- monotherapy. Expand
The use of atypical antipsychotics beyond psychoses: efficacy of quetiapine in bipolar disorder
Manic and mixed episodes have been the best studied, and quetiapine was found to be effective either as monotherapy or as adjunctive therapy in both randomized clinical trials and open-label studies. Expand
The management of schizophrenia: focus on extended-release quetiapine fumarate
  • J. Peuskens
  • Medicine
  • Neuropsychiatric disease and treatment
  • 2011
In patients who experienced insufficient efficacy or poor tolerability on their previous antipsychotic, switching to quetiapine XR significantly improved efficacy compared with the previous treatment, and once-daily dosing may improve patient adherence, which may impact positively on patient outcomes. Expand
Effect of Quetiapine and Norquetiapine on Anxiety and Depression in Major Psychoses Using a Pharmacokinetic Approach
The results of this study confirm the efficacy of quetiapine on both anxious and depressive symptoms, showing a correlation between plasma concentrations and clinical efficacy only in patients with bipolar depression. Expand
Pharmacokinetic Variability of Quetiapine and the Active Metabolite N-desalkylquetiapine in Psychiatric Patients
Age 65 years or older and comedication with CYP3A4 inducers affected the serum levels of both agents, but the relative impact was greater on quetiapine. Expand
Quetiapine XR – A New Retard Formulation in the Treatment of Schizophrenia
  • 2009
introduction of atypical antipsychotics. These second-generation antipsychotics (SGAs) share similarities in terms of their side effect and receptor profiles, e.g. lower affinity to dopamine D2 andExpand
Neurobiological bases of quetiapine antidepresant effect in the bipolar disorder.
Quetiapine’s action on glutamatergicand GABAergic receptors represents an interesting object of research, together with a potential neuroprotective effect that have already been observed in animal models. Expand
Pharmacological Management of Bipolar Depression: Acute Treatment, Maintenance, and Prophylaxis
The pharmacological treatment of bipolar depression mostly consists of combinations of at least two drugs, including mood stabilizers (lithium and anticonvulsants), atypical antipsychotics, and antidepressants. Expand